Prostate Cancer from a Nuclear Oncology Perspective

1. Introduction – prostate cancer from the point of view of the author and the history of imaging.- 2. Integrated summary of research on radioiodinated estramustine phosphate and estramustine binding protein antibody in prostate cancer treatment.- 3. Summary of Diagnostic Accuracy of 18F-Fluorocholine PET/CT in Prostate Cancer Staging.- 4. Overview of 18F-NaF PET/CT Imaging.- 5. 18F-Fluciclovine (18F-FACBC) Positron Emission Tomography in Prostate Cancer.- 6. PSMA-PET in prostate cancer.- 7. 18F-FLT PET/CT in Prostate Adenocarcinoma .- 8. 18F-FDHT-PET Imaging in the Management of Hormone-Dependent  Prostate Cancer.- 9. Immunoscintigraphy and radioimmunotherapy of prostate cancer incuding own personal journey -anti-PAP and anti-PSMA antibodies.- 10. Briefly about radiation therapy.- 11. PET/CT for Radiation Therapy Planning of Prostate Cancer .- 12. Brief overview of prostate cancer treatment modalities.- 13. Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer.- 14. Lu-177-PSMA treatment in prostate cancer.- 15. Clinical Experience in 225Ac-PSMA.- 16. Multicenter trials prostate radioligand therapy (PRLT) in castration resistant cancer.- 17. Meta-analyses and systematic reviews (own experience) in prostate cancer.- 18. Own history of cancer suspicions.- 19. Public appearance because of nuclear oncology (pictorial essay).- . Appendix - ISUP and PI-RADS classifications.